Hyperleukotrieneuria in patients with allergic and inflammatory disease.

Cysteinyl leukotrienes (CysLTs: leukotrienes C(4), D(4), and E(4)) have long been implicated in the pathogenesis of asthma and several allergic diseases. LTE(4) has been identified as a major metabolite of LTC(4), and urinary LTE(4) (U-LTE(4)) is considered as the most reliable analytic parameter for monitoring the endogenous synthesis of CysLTs. From recent studies on the U-LTE(4) associated with adult stable asthma we identified four factors for hyperleukotrieneuria, namely, aspirin intolerance, eosinophilic nasal polyposis (ENP), vasculitis, and severe asthma. In ENP, there is prominent infiltration of eosinophils in the sinus and polyp tissues, which is linked to adult asthma and aspirin sensitivity, and ENP is the most important factor for the overproduction of CysLTs in asthmatics. We also demonstrated that anaphylaxis and eosinophilic pneumonia (EP) are associated with a marked increase in the U-LTE(4) concentration. Under these disease conditions, U-LTE(4) may be one of the candidate biomarkers. Moreover, the changes in U-LTE(4) concentrations may provide valuable information concerning therapeutic targets.

[1]  N. Higashi,et al.  Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  N. Higashi,et al.  Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. , 2008, The Journal of allergy and clinical immunology.

[3]  N. Higashi,et al.  Increased urinary leukotriene E4 concentration in patients with eosinophilic pneumonia , 2008, European Respiratory Journal.

[4]  M. Taniguchi,et al.  Salicylamide‐induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite , 2008, Allergy.

[5]  N. Higashi,et al.  Role of cysteinyl-leukotrienes in the pathogenesis of nasal polyposis in patients with asthma , 2007 .

[6]  F. Simons,et al.  Risk assessment in anaphylaxis: current and future approaches. , 2007, The Journal of allergy and clinical immunology.

[7]  M. Taniguchi,et al.  Quantification of leukotriene B4 glucuronide in human urine. , 2007, Prostaglandins & other lipid mediators.

[8]  Michael A Kaliner,et al.  The diagnosis and management of sinusitis: a practice parameter update. , 2005, The Journal of allergy and clinical immunology.

[9]  V. Cottin,et al.  Eosinophilic pneumonias , 2005, Allergy.

[10]  C. Bachert,et al.  Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. , 2005, The Journal of allergy and clinical immunology.

[11]  Joint Task Force on Practice Parameters.  The diagnosis and management of anaphylaxis: an updated practice parameter. , 2005, The Journal of allergy and clinical immunology.

[12]  R. Nicklas.  The diagnosis and management of anaphylaxis , 2005 .

[13]  A. Higashi,et al.  Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. , 2004, Journal of Allergy and Clinical Immunology.

[14]  S. Dahlén,et al.  Measuring quality of life in patients with sleep apnoea: whose life is it anyway? , 2004, Thorax.

[15]  M. Malice,et al.  Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation , 2004, Thorax.

[16]  A. Higashi,et al.  Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. , 2004, The Journal of allergy and clinical immunology.

[17]  R. Bush,et al.  Alternaria-induced asthma. , 2004, The Journal of allergy and clinical immunology.

[18]  Hiroshi Tanaka,et al.  High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. , 2003, Chest.

[19]  N. Higashi,et al.  Nasal blockage and urinary leukotriene E4 concentration in patients with seasonal allergic rhinitis , 2003, Allergy.

[20]  Keiko Saito,et al.  The Roles of Cysteinyl Leukotrienes in Eosinophilic Inflammation of Asthmatic Airways , 2003, International Archives of Allergy and Immunology.

[21]  H. Frierson,et al.  Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. , 2003, The Journal of allergy and clinical immunology.

[22]  Masashi Kobayashi,et al.  Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. , 2002, The Journal of allergy and clinical immunology.

[23]  R. Panettieri.  Cellular and molecular mechanisms regulating airway smooth muscle proliferation and cell adhesion molecule expression. , 1998, American journal of respiratory and critical care medicine.

[24]  Dahlén.  Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  M. Kumlin,et al.  Urinary excretion of inflammatory mediators during allergen‐induced early and late phase asthmatic reactions , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  Mita,et al.  Correlation among urinary eosinophil protein X, leukotriene E4, and 11‐dehydrothromboxane B2 in patients with spontaneous asthmatic attack , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  S. Dahlén,et al.  Can asthma be studied in the urine? , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  H. Mita,et al.  Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. , 1997, International archives of allergy and immunology.

[29]  H. Mita,et al.  Efficient method for the quantitation of urinary leukotriene E4: extraction using an Empore C18 disk cartridge. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[30]  H. Mita,et al.  Urinary leukotriene E4 and 11‐dehydrothromboxane B2 in patients with aspirin‐sensitive asthma , 1997, Allergy.

[31]  E. Israel,et al.  Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. , 1995, The Journal of allergy and clinical immunology.

[32]  W. Henderson.  The Role of Leukotrienes in Inflammation , 1994, Annals of Internal Medicine.

[33]  T. Lee,et al.  Urinary leukotriene E4 in bronchial asthma. , 1992, The European respiratory journal.

[34]  A. Togias,et al.  The role of leukotrienes in allergic rhinitis: a review. , 1991, The American review of respiratory disease.

[35]  J. Zakrzewski,et al.  The biotransformation in vitro of cysteinyl leukotrienes in blood of normal and asthmatic subjects. , 1989, Prostaglandins.

[36]  M. Okuda,et al.  The role of leukotriene D4 in allergic rhinitis. , 1988, Annals of allergy.

[37]  M. Underner,et al.  [Role of the leukotrienes in asthma]. , 1986, Allergie et immunologie.

[38]  H. Bisgaard,et al.  Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans , 1986, Clinical allergy.

[39]  G. Shackelford,et al.  Chronic eosinophilic pneumonia. , 1971, Radiology.

[40]  C. Carrington,et al.  THE EOSINOPHILIC PNEUMONIAS , 1969, Medicine.

[41]  W. Alberts.  Eosinophilic Lung Diseases , 2009 .

[42]  A. Mori,et al.  Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. , 2007, Allergology international : official journal of the Japanese Society of Allergology.

[43]  J. Drazen.  Leukotrienes in asthma. , 2003, Advances in experimental medicine and biology.

[44]  D. Woodward,et al.  Studies on leukotriene D4 as an eosinophil chemoattractant. , 1991, Drugs under experimental and clinical research.